Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
- APL-2 in Geographic Atrophy (GA) and Paroxysmal Nocturnal Hemoglobinuria (PNH) On Track to Advance into Phase 3 Trials in 2H18 - - Cash Position of $152.9 Million at Quarter-End; April 2018 Public...
-
CRESTWOOD, Ky. and WALTHAM, Mass., April 23, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
-
CRESTWOOD, Ky. and WALTHAM, Mass., April 18, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
-
CRESTWOOD, Ky. and WALTHAM, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
-
CRESTWOOD, Ky. and WALTHAM, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
-
- Initiation of Phase 3 Programs in Geographic Atrophy (GA) and Paroxysmal Nocturnal Hemoglobinuria (PNH) Planned for 2018; Phase 2 Proof-of-Concept (POC) Data Anticipated in Autoimmune Hemolytic...
-
CRESTWOOD, Ky. and CAMBRIDGE, Mass., Feb. 23, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company developing a platform of novel...
-
CRESTWOOD, Ky. and CAMBRIDGE, Mass., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company developing a platform of novel...
-
CRESTWOOD, Ky. and CAMBRIDGE, Mass., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company developing a platform of novel...
-
CRESTWOOD, Ky. and CAMBRIDGE, Ma., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...